Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.79
-0.12 (-1.35%)
At close: Aug 13, 2025, 4:00 PM
8.84
+0.05 (0.55%)
After-hours: Aug 13, 2025, 5:06 PM EDT
Emergent BioSolutions Employees
Emergent BioSolutions had 900 employees as of December 31, 2024. The number of employees decreased by 700 or -43.75% compared to the previous year.
Employees
900
Change (1Y)
-700
Growth (1Y)
-43.75%
Revenue / Employee
$946,222
Profits / Employee
$155,000
Market Cap
468.96M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 900 | -700 | -43.75% |
Dec 31, 2023 | 1,600 | -900 | -36.00% |
Dec 31, 2022 | 2,500 | 84 | 3.48% |
Dec 31, 2021 | 2,416 | 216 | 9.82% |
Dec 31, 2020 | 2,200 | 366 | 19.96% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EBS News
- 1 day ago - Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally - Seeking Alpha
- 5 days ago - Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Emergent BioSolutions Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 16 days ago - Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives - GlobeNewsWire
- 16 days ago - New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate - GlobeNewsWire